EE200000486A - Fosfolipaasensüümide inhibiitorid, neid sisaldav farmatseutiline kompositsioon ning meetod põletikulise reaktsiooni raviks imetajal - Google Patents

Fosfolipaasensüümide inhibiitorid, neid sisaldav farmatseutiline kompositsioon ning meetod põletikulise reaktsiooni raviks imetajal

Info

Publication number
EE200000486A
EE200000486A EEP200000486A EEP200000486A EE200000486A EE 200000486 A EE200000486 A EE 200000486A EE P200000486 A EEP200000486 A EE P200000486A EE P200000486 A EEP200000486 A EE P200000486A EE 200000486 A EE200000486 A EE 200000486A
Authority
EE
Estonia
Prior art keywords
mammal
treating
pharmaceutical composition
composition containing
inflammatory response
Prior art date
Application number
EEP200000486A
Other languages
English (en)
Estonian (et)
Inventor
S. Seehra Jasbir
Kaila Neelu
C. Mckew John
Lovering Frank
E. Bemis Jean
Xiang Yibin
Original Assignee
Genetics Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Inc. filed Critical Genetics Institute, Inc.
Publication of EE200000486A publication Critical patent/EE200000486A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200000486A 1998-02-25 1999-02-24 Fosfolipaasensüümide inhibiitorid, neid sisaldav farmatseutiline kompositsioon ning meetod põletikulise reaktsiooni raviks imetajal EE200000486A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3006298A 1998-02-25 1998-02-25
PCT/US1999/003899 WO1999043651A2 (en) 1998-02-25 1999-02-24 Inhibitors of phospholipase enzymes

Publications (1)

Publication Number Publication Date
EE200000486A true EE200000486A (et) 2002-02-15

Family

ID=21852314

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000486A EE200000486A (et) 1998-02-25 1999-02-24 Fosfolipaasensüümide inhibiitorid, neid sisaldav farmatseutiline kompositsioon ning meetod põletikulise reaktsiooni raviks imetajal

Country Status (19)

Country Link
EP (1) EP1056719A2 (no)
JP (1) JP2002504539A (no)
KR (1) KR20010041343A (no)
CN (1) CN1299347A (no)
AU (1) AU2782699A (no)
BG (1) BG104780A (no)
BR (1) BR9908280A (no)
CA (1) CA2322161A1 (no)
EA (1) EA200000868A1 (no)
EE (1) EE200000486A (no)
HR (1) HRP20000552A2 (no)
HU (1) HUP0100757A3 (no)
ID (1) ID27280A (no)
IL (1) IL137718A0 (no)
NO (1) NO20004220L (no)
PL (1) PL342995A1 (no)
SK (1) SK12742000A3 (no)
TR (1) TR200002446T2 (no)
WO (1) WO1999043651A2 (no)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1177186B1 (en) * 1999-05-05 2004-03-31 Aventis Pharma Limited Ureas and their use as cell adhesion modulators
JP2004513076A (ja) 2000-07-25 2004-04-30 メルク エンド カムパニー インコーポレーテッド 糖尿病治療で有用なn−置換インドール類
NZ539682A (en) 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
US20030013656A1 (en) 2001-05-03 2003-01-16 Bing Wang Pyruvate derivatives
DE60221391T2 (de) 2001-06-20 2008-04-17 Wyeth Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7291639B2 (en) 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7189751B2 (en) * 2001-06-25 2007-03-13 Nippon Soda Co., Ltd. Oxa(thia)zolidine compounds, process for preparation thereof and anti-inflammatory agents
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
SI1451154T1 (sl) * 2001-12-03 2008-06-30 Wyeth Corp Zaviralci citosolne fosfolipaze a2
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
TWI334778B (en) * 2001-12-03 2010-12-21 Wyeth Corp Inhibitors of cytosolic phospholipase a2
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US6797708B2 (en) * 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
US7101875B2 (en) 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
JP4340232B2 (ja) 2002-08-29 2009-10-07 メルク エンド カムパニー インコーポレーテッド 抗糖尿病活性を有するインドール類
NZ538031A (en) 2002-08-29 2007-10-26 Merck & Co Inc Indoles having anti-diabetic activity
MXPA05004929A (es) 2002-11-07 2005-08-18 Akzo Nobel Nv Indoles utiles en el tratamiento de enfermedades relacionadas a receptor de androgeno.
DK1569899T3 (da) 2002-12-10 2006-10-23 Wyeth Corp Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
BR0316574A (pt) 2002-12-10 2005-10-04 Wyeth Corp Derivados de ácido acético 3-carbonil-1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CA2509191A1 (en) 2002-12-10 2004-06-24 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
TW200510305A (en) * 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
CN101006053A (zh) 2004-06-18 2007-07-25 比奥里波克斯公司 用于治疗炎症的吲哚
CA2577846A1 (en) 2004-08-23 2006-03-02 Wyeth Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
JP2008510814A (ja) 2004-08-23 2008-04-10 ワイス Pai−1阻害剤としてのピロロ−ナフチル酸
AU2005298986A1 (en) * 2004-10-27 2006-05-04 F. Hoffmann-La Roche Ag New indole or benzimidazole derivatives
ATE501119T1 (de) * 2005-01-19 2011-03-15 Biolipox Ab Entzündungshemmende indol-derivate
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
TW200718687A (en) * 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
EP1919866A2 (en) 2005-08-17 2008-05-14 Wyeth a Corporation of the State of Delaware Substituted indoles and use thereof
US8168673B2 (en) 2008-01-22 2012-05-01 Oxagen Limited Compounds having CRTH2 antagonist activity
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
UA121539C2 (uk) 2011-09-02 2020-06-25 Інсайт Холдинґс Корпорейшн Гетероцикліламіни як інгібітори рі3к
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
HRP20180061T1 (hr) 2012-07-17 2018-02-23 Glaxosmithkline Intellectual Property (No. 2) Limited Indolkarbonitrili kao selektivni modulatori androgenskih receptora
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
UA122332C2 (uk) 2015-02-27 2020-10-26 Інсайт Корпорейшн Солі інгібітора pi3k і способи їх отримання
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
MX2020012826A (es) 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
PT3860998T (pt) 2018-10-05 2024-04-02 Annapurna Bio Inc Compostos e composições para o tratamento de condições associadas à atividade do recetor apj

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE314373B (no) * 1966-04-12 1969-09-08 Sumitomo Chemical Co
FR1492929A (fr) * 1966-05-11 1967-08-25 Roussel Uclaf Nouveaux 1-(omega-carboxyalcoyl) indoles substitués et procédé de préparation
US3505354A (en) * 1967-05-18 1970-04-07 Geigy Chem Corp 2-methyl-3-p-halobenzoylindole-n-aliphatic acids
DE1816335A1 (de) * 1968-12-21 1970-07-09 Thiemann Gmbh Chem Pharm Fabri Verfahren zur Herstellung von [2-Methyl-5-alkoxy-3-acyl-indol-1]-essigsaeuren und deren Estern
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
ES2045420T3 (es) * 1988-04-13 1994-01-16 Ici America Inc Amidas ciclicas.
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5290798A (en) * 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
JP3332234B2 (ja) * 1992-05-13 2002-10-07 シンテックス(ユー・エス・エイ)・インコーポレイテッド アンギオテンシンii拮抗剤としての置換インドール類
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
DE4338770A1 (de) * 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
ES2208935T3 (es) * 1996-08-01 2004-06-16 Merckle Gmbh Acidos acil-pirrol-dicarboxilicos y acidos acil-indol-dicarboxilicos, asi como sus derivados como inhibidores de la fosfolipasa a2 citosolica.
EP0922028A1 (en) * 1996-08-26 1999-06-16 Genetics Institute, Inc. Inhibitors of phospholipase enzymes

Also Published As

Publication number Publication date
NO20004220D0 (no) 2000-08-23
NO20004220L (no) 2000-10-05
WO1999043651A3 (en) 1999-12-16
HRP20000552A2 (en) 2001-04-30
IL137718A0 (en) 2001-10-31
HUP0100757A3 (en) 2001-11-28
TR200002446T2 (tr) 2000-12-21
AU2782699A (en) 1999-09-15
PL342995A1 (en) 2001-07-16
BR9908280A (pt) 2000-10-31
EP1056719A2 (en) 2000-12-06
CN1299347A (zh) 2001-06-13
BG104780A (en) 2001-10-31
EA200000868A1 (ru) 2001-04-23
ID27280A (id) 2001-03-22
SK12742000A3 (sk) 2001-05-10
WO1999043651A2 (en) 1999-09-02
KR20010041343A (ko) 2001-05-15
HUP0100757A1 (hu) 2001-08-28
JP2002504539A (ja) 2002-02-12
CA2322161A1 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
BR0001422B1 (pt) aparelho e mÉtodo de reproduÇço.
EE200000522A (et) Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
NO20004550D0 (no) Enzyminhibitorer
NO20003096D0 (no) Sammensetninger og fremgangsmÕter for behandling av ADD
EE200000488A (et) Fosfolipaasensüümide inhibiitorid ja farmatseutilised kompositsioonid
AU2001270054A1 (en) Method and system for determining personal characteristics of an individual or group
DE69914006D1 (de) DVD-Aufzeichnungsanordnung und -verfahren
DK199901519A (da) I form af små molekyler foreliggende inhibitorer af rotamase-enzymaktivitet
DK199901518A (da) I form af små molekyler foreliggende inhibitorer af rotamase-enzymaktivitet
PT1105123E (pt) Composicoes farmaceuticas contendo inibidores da lipase e quitosano
FI965019A7 (fi) Entsyymi-inhibiittoreita
NO20006700L (no) Innretning og fremgangsmåte for laserbelegging
NO20004220L (no) Inhibitorer av fosfolipaseenzymer
FI982095L (fi) Menetelmä muistin toteuttamiseksi ja muistijärjestely
EP1061800A4 (en) COMPOSITIONS AND METHODS FOR MODULATING THE VASCULARIZATION
MXPA03003682A (es) Metodo para determinar la coagulabilidad y el potencial hemostatico globales.
DK1112003T3 (da) Ny sammensætning og anvendelse
FI971801A0 (fi) Parannettu ääniviestijärjestelmä ja menetelmä sen käyttämiseksi
DE69912179D1 (de) Plattenwiedergabegerät und Verfahren
DE69932573D1 (de) Wiedergabeverfahren und Wiedergabegerät
DE69903319D1 (de) Fkbp inhibitoren
NO20015318L (no) Metode for signering og autentisering av meldinger
NO995564D0 (no) Fremgangsmåte og konstruksjon for inhibisjon av cellemigrering
NO20002436D0 (no) Sammensetning og fremgangsmÕte for fjerning av fosfationinnholdet i vann
FI981029L (fi) Menetelmä ja järjestely testaukseen